Tran, Ben
Carvajal, Richard D.
Marabelle, Aurelien
Patel, Sandip Pravin
LoRusso, Patricia M.
Rasmussen, Erik
Juan, Gloria
Upreti, Vijay V.
Beers, Courtney
Ngarmchamnanrith, Gataree
Schöffski, Patrick
Funding for this research was provided by:
Amgen Inc.
Article History
Received: 11 June 2018
Accepted: 10 September 2018
First Online: 25 September 2018
Ethics approval and consent to participate
: All procedures were approved by the following institutional review boards or ethics committees: Commissie Medische Ethiek van de Universitaire Ziekenhuizen KU Leuven; Ethikkommision; Comité de Protection des Personnes Ile de France; Columbia University IRB; UCSD Human Research Protections Program; WIRB; and Melbourne Health Human Research Ethics Committee.
: All patients provided written, informed consent.
: BT has received a grant, consulting fees, and honoraria from Amgen Inc. RDC is a consultant for AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Foundation Medicine, Immunocore, Incyte, Merck, Novartis, and Roche/Genentech, has served on clinical advisory boards for Aura Biosciences and Rgenix, and has served on a scientific advisory board for Chimeron. SPP has received research support from Amgen Inc. ER, GJ, VVU, and GN are employees of and own stock in Amgen Inc. At the time of this study, CB was an employee of Amgen Inc. AM, PML, and PS have no conflicts to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.